There were many reasons for the U.S. Senate not to confirm RFK Jr. as HHS Secretary. Reasons that transcended politics. Nonetheless, Senate Republicans confirmed him today for that post. Some of them had voiced serious concerns before including one physician Senator, Dr. Bill Cassidy, but they all voted for Kennedy anyway. All except Mitch McConnell, […]
Initial reactions to RFK Jr. being HHS Secretary Read More »
When I think of so-called aging supplements, visions of snake oil dance in my head. Possible benefits of supplements more generally have mostly not held up to long-term research. Supplements have risks too and so do purported longevity supplements. These pills claiming to fight aging are more in the realm of stem cell supplements that
Weekly reads: Altos Labs aging supplements pub, destructive NIH cuts, FDA warning, HSCs Read More »
How will things change at the FDA under the second Trump Administration? It’s a key question for our field but not easy to answer. Most likely there will be more instability at the agency. Some leaders, like of CDER, have already left. in my overall regenerative medicine predictions for 2025, I’ve included more predictions about
Weekly reads: FDA modernization, TFs on the brain, mortality timer, pluripotent trials Read More »
I’ve written before about concerns related to longevity research hype from Harvard professor David Sinclair. The media often eats up statements about longevity from Sinclair and a few other scientists in that space. There is also endless coverage of the latest exploits of wealthy health influencer Bryan Johnson. For that reason it was refreshing to
Refreshing WSJ piece on longevity ‘guru’ David Sinclair Read More »
What do you think of when I mention Stanford professor Mike Snyder and self-help guru Tony Robbins together? I would not necessarily have imagined them forming a connection but science is full of surprises. I’ve admired Snyder’s work in genetics for a long time. I’m most familiar these days with Robbins for his interest in
Gene editing continues to advance both in the clinic trial arena and at more basic science levels including a report on a new approach called click editing. The two gene editing papers below highlight the variety of tools now available. Gene Editing papers including click editing Click editing enables programmable genome writing using DNA polymerases
Recommended reads: click editing, CRISPR v. progeria, diapause transcriptional program Read More »
Would you guess that Elon Musk might be into using biotechnology in a high-profile way to try to live far longer than usual, say to age 150? That would have been my assumption. There are countless things about Elon Musk that I really don’t like. I also don’t see many issues on which we are
Something Elon Musk & I agree on: pushing back on anti-aging bluster Read More »
Readers of The Niche have asked me many questions about stem cells for autoimmune disease but the puzzle of why women get these conditions more often than men hasn’t come up before here. For instance, why is MS so much more common in women than men? It’s remained somewhat of a mystery over the years.
The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and
Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »
Let’s start this week’s digest with a discussion of clonal expansion and mutations during cell and gene therapy development. Here’s the article that brought this to mind. Sickle cell gene therapy process may cause cancer-linked mutations in blood stem cells, Fierce Biotech. Clonal expansion This is a story about a non-CRISPR gene therapy using a